Results 161 to 170 of about 7,663 (213)

Esketamine

Reactions Weekly
  +8 more sources

NICE reconsiders esketamine for depression

BMJ, 2020
The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the use of esketamine for treatment resistant depression, after feedback showed that it could benefit some patients. Guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be ...
openaire   +2 more sources

Esketamine

Reactions Weekly, 2022
  +4 more sources

Esketamine for treatment-resistant depression

Drug and Therapeutics Bulletin, 2020
Generic name: Esketamine hydrochloride Brand name: Spravato Formulation: 28mg in 0.2ml nasal spray solution Market Authorisation holder: Janssen-Cilag International NV Indication: Treatment resistant
openaire   +2 more sources

Esketamine: Less Drowsiness, More Analgesia

Anesthesia & Analgesia
Racemic ketamine is a 1:1 mixture of 2 enantiomers that turn light in opposite direction: Dextrorotatory esketamine is approximately 4 times more affine for the N-methyl-D-aspartate (NMDA) receptor than levorotatory arketamine, which may explain why esketamine is about twice as potent as an analgesic and anesthetic as the racemate.
Georges, Mion, Sabine, Himmelseher
openaire   +2 more sources

Ketamin und Esketamin

Nervenheilkunde
ZUSAMMENFASSUNGKetamin blickt bereits auf eine längere Geschichte der Anwendung in der Psychiatrie zurück. Insbesondere ist es in den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden und ist mit dem Enantiomer Esketamin in Deutschland für diese Indikation zugelassen.
Cornelius Schüle, Gabi Koller, Uwe Herwig   +2 more
openaire   +1 more source

Esketamine for Postpartum Suicidality

Biological Psychiatry, 2021
Catarina, Machado, Acioly L T, Lacerda, Rodrigo A, Bressan, Cristiano, Noto   +3 more
openaire   +2 more sources

Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Journal of Affective Disorders, 2021
Anees Bahji, Carlos A Zarate Jr
exaly  

Esketamine

Reactions Weekly, 2019
openaire   +2 more sources

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

American Journal of Psychiatry, 2021
Joshua D Rosenblat, Charles B Nemeroff, Gerard Sanacora   +2 more
exaly